#RecurrenceRisk - Twitter Hashtag

over 1 year ago

Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidcancer (PTC), called Thyroid GuidePx®. DOI: https://t.co/6Vs4agpizD Read our article: https://t.co/aYMMW54Y9Q

2

281

20

13

254K

Breastcancer.org

@Breastcancerorg

over 2 years ago

Isoflavones, weak estrogen-like compounds found in soy, may reduce the risk of #breastcancer coming back (recurrence), as well as the risk of dying from breast cancer, according to a study. https://t.co/rHwIUJPoz1 #nutrition #recurrencerisk #breastcancerresearch

Breastcancerorg's tweet photo. Isoflavones, weak estrogen-like compounds found in soy, may reduce the risk of #breastcancer coming back (recurrence), as well as the risk of dying from breast cancer, according to a study. https://t.co/rHwIUJPoz1 #nutrition #recurrencerisk #breastcancerresearch https://t.co/wZ2hltxtry

0

3

1

0

190

Annals of Surgical Oncology @AnnSurgOncol

over 2 years ago

#AudioVisualAbstract : Enhanced Clinical Utility of Molecular Budding Signature as a #RecurrenceRisk Determinant in Stage II and III #ColonCancer Patients https://t.co/1TrkUR6LJK

0

3

1

0

973

CancerDotNet @CancerDotNet

about 4 years ago

#DYNAMIC study: #LiquidBiopsy may help reduce the need for #Chemotherapy after surgery for some people with stage 2 #ColonCancer without impacting #RecurrenceRisk https://t.co/ZYgnkzf1Kl #ctDNA #CRCSM #AdjuvantTherapy @PeterMacCC #CRCSM

0

3

2

0

HTG - Selina Gaertner @HtgSelina

over 4 years ago

Join our #Webinar Special tomorrow on INTERNATIONAL's WOMEN'S DAY with BioNordika and @DurvizDiagnstic on #BreastCancer #RecurrenceRisk assessment and #MolecularSubtyping using #HTGEdgeSeq Technology, Register Now: https://t.co/i4NTqlNfzE

HtgSelina's tweet photo. Join our #Webinar Special tomorrow on INTERNATIONAL's WOMEN'S DAY with BioNordika and @DurvizDiagnstic on #BreastCancer #RecurrenceRisk assessment and #MolecularSubtyping using #HTGEdgeSeq Technology, Register Now: https://t.co/i4NTqlNfzE https://t.co/WOJNdrMCQK

0

Dr. Iván R. González

@Dr_Ivanoncologo

over 5 years ago

#GI21 @ASCO #ctDNA #analysis for #assessment of #recurrenceRisk, #benefit of #adjuvantTherapy, and early relapse detection after #treatment in #colorectalCancer . @ASCO_pubs @Zain_BaigMD @TarazonaNoelia @EricaTsangMD @smelrefai

Dr_Ivanoncologo's tweet photo. #GI21 @ASCO
#ctDNA #analysis for #assessment of #recurrenceRisk, #benefit of #adjuvantTherapy, and early relapse detection after #treatment in #colorectalCancer
.
@ASCO_pubs @Zain_BaigMD @TarazonaNoelia @EricaTsangMD @smelrefai https://t.co/BBCjexbfnU

Pashtoon Kasi MD, MS

@pashtoonkasi

over 5 years ago

#GI21 #ctDNA 🩸🧬 Changing paradigms. More data to show that it is a dynamic marker. More than just prognostic. Ability to potentially change ctDNA➕➡️➖. Lead time of ~8 months for relapse. #OncoAlert Onc